Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

Author： Keizer Ron

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.30, Iss.4, 2012-08, pp. : 1519-1530

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Design Issues in Dose-Finding Phase I Trials for Combinations of Two Agents

By Fan Shenghua Kelly

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 509-523

Taylor & Francis Ltd

Access to resources Recommend Favorite

Adaptive Bayesian Design for Phase I Dose-Finding Trials Using a Joint Model of Response and Toxicity

By Wang Meihua

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 1, 2010-01 ,pp. : 125-144

Taylor & Francis Ltd

Access to resources Recommend Favorite

Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer

By Curry Eardie Murry Daryl Yoder Christy Fife Karen Armstrong Victoria Nakshatri Harikrishna O’Connell Michael Sweeney Christopher

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 299-305

Springer Publishing Company

Access to resources Recommend Favorite

Ethical Issues in Phase I Cancer Clinical Trials

By Peppercorn Jeffrey

International Journal of Pharmaceutical Medicine, Vol. 20, Iss. 4, 2006-01 ,pp. : 233-242

Adis International

Access to resources Recommend Favorite

Optimal Two-Stage Randomized Multinomial Designs for Phase II Oncology Trials

By Sun Linda

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 485-493

Taylor & Francis Ltd

Access to resources Recommend Favorite